Loading...
In a recently published meta-analysis of placebo-controlled cardiovascular prevention trials, treatment with daily low-dose aspirin for more than 5 years significantly lowered long-term colorectal cancer incidence and mortality (JW Gen Med Dec 21 2010). In a new meta-analysis, investigators now examine the effect of daily aspirin on overall cancer mortality.
Researchers combined patient-level data from eight cardiovascular prevention trials, in which 25,000 patients took daily aspirin (any dose) or placebo (or no treatment) for at least 4 years. While the trials were in progress, cancer mortality was about 20% lower overall among patients assigned to aspirin, with the greatest effect at more than 5 years after randomization.
Long-term data we…